Choose your country to see the products for your location
Researchers from the University of Belgrade succeeded in making state-wide newborn screening become a reality through a stepwise plan that included a laboratory validation step, a feasibility study on a smaller cohort of newborns, and finally the transition to a national program.
Researchers from the Amsterdam University Medical Centre recently published a study on a distinct subclass of head and neck cancers in collaboration with MRC Holland scientists.
P105 Glioma just received a major update that enables a more complete characterization of the genetic landscape of gliomas. The recently released E1 version includes two probes specific for the common TERT C228T and C250T SNVs.
ME034 Multi-locus Imprinting just received a major update, with the recently released D1 version featuring several new and improved target and reference probes that expand the differentially methylated regions investigated and ensure an even more robust assay output.
D007 Acute Lymphoblastic Leukemia just received an update, with version B1 featuring new probes that increase the coverage of ALL-relevant regions and target genes of emerging interest for ALL.
Effective from 1 January 2025, we will be implementing a price increase of approximately 1.9% on most of our products.
D001 Hereditary Cancer Panel 1 recently received an update, with version D1 featuring several new modified probes, increasing the performance and coverage of the product.
The product pages on our website are in the process of receiving an exciting makeover. So far, we have transitioned the product pages of our IVD-certified products to the new design, but gradually the product pages of our RUO-products will also follow suit.
As part of our upcoming IVDR transition, we are working on a new product description template that will make our product descriptions easier to read, maintain and translate.
MLPA General Protocol and MS-MLPA General Protocol have a fresh design and have undergone significant restructuring to improve user-friendliness.
Join our mailing list to receive the latest information about our products, technologies and website.